UEGW 2021 | Pfizer Información Médica

La información de esta página es seleccionada de materiales de congresos, áreas terapéuticas y de enfermedades. No pretende servir como una descripción general completa de todos los contenidos mencionados

Volver a Congresos

Póster

Chiorean MV, Ha C, Armuzzi A, Lawendy N, Mundayat R, Salese L, Woolcott JC, Su C, Dotan I Octubre 5, 2021 UEGW 2021 Colitis Ulcerativa

Analysis of infections of interest in patients treated with tofacitinib in the ulcerative colitis clinical programme

Ver Presentación

Póster

Dubinsky MC, D'Haens GR, Sandborn WJ, Ng SC, Panés J, Su C, Lawendy N, Lazariciu I, Gardiner S, Mundayat R, Kulisek N, Modesto I, Torres J Octubre 5, 2021 UEGW 2021 Colitis Ulcerativa

Association between efficacy outcomes and prior duration of remission in patients with ulcerative colitis treated with tofacitinib 10 mg twice daily who were in stable remission and either dose-reduced to tofacitinib 5 mg twice daily or remained on 10 mg twice daily: 6-month data from the double-blind, randomised RIVETING study

Ver Presentación

Póster

Armuzzi A, Hart A, Sharma PP, Hoskin B, Woolcott J, Mammar N, Hennessy F, Cappelleri JC, Milligan G, Dignass A Octubre 5, 2021 UEGW 2021 Colitis Ulcerativa

Characteristics and real world treatment history of patients treated with tofacitinib for ulcerative colitis in Europe

Ver Presentación

Póster

Loftus Jr EV, Armuzzi A, Baumgart DC, Gecse KB, Connelly SB, Su C, Kwok KK, Guo X, Kinnucan JA Octubre 5, 2021 UEGW 2021 Colitis Ulcerativa

Clostridium difficile infection in patients treated with tofacitinib in the ulcerative colitis clinical programme

Ver Presentación

Póster

Lee SD, Allegretti JR, Steinwurz F, Connelly SB, Lawendy N, Paulissen J, Gecse KB Octubre 5, 2021 UEGW 2021 Colitis Ulcerativa

Evaluation of the efficacy of tofacitinib as maintenance therapy in patients with ulcerative colitis stratified by OCTAVE Sustain baseline endoscopic subscore

Ver Presentación

Presentación Oral

Winthrop KL, Melmed GY, Vermeire S, Panés J, Kulisek N, Mundayat R, Lawendy N, Su C Octubre 5, 2021 UEGW 2021 Colitis Ulcerativa

Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib: results from the Phase 2 and Phase 3 clinical programmes

Ver Presentación

Póster

Sandborn WJ, Dubinsky MC, Torres J, Vermeire S, Kotze PG, Su C, Lawendy N, Paulissen J, Mundayat R, Gardiner S, Kulisek N, Modesto I, D'Haens GR Octubre 5, 2021 UEGW 2021 Colitis Ulcerativa

Impact of prior tumour necrosis factor inhibitor failure and prior corticosteroid use on the maintenance of efficacy of tofacitinib following dose reduction in patients with ulcerative colitis who were in stable remission: 6-month data from the double-blind, randomised RIVETING study

Ver Presentación

Presentación Oral

Colombel J-F, Osterman MT, Ibanez P, Vermeire S, Irving PM, Gardiner S, Connelly SB, Mundayat R, Lawendy N, Su C, Reinisch W Octubre 5, 2021 UEGW 2021 Colitis Ulcerativa

Maintenance of remission with tofacitinib in patients with ulcerative colitis: final results of a subpopulation analysis from an open-label, long-term extension study, OCTAVE Open

Ver Presentación

Póster

D'Haens GR, Dubinsky MC, Regueiro M, Santana GO, Torres J, Kulisek N, Gardiner S, Mundayat R, Paulissen J, Lawendy N, Su C, Modesto I, Sandborn WJ Octubre 5, 2021 UEGW 2021 Colitis Ulcerativa

Non-invasive predictors of maintaining remission in patients with moderately to severely active ulcerative colitis treated with tofacitinib who dose-reduced from tofacitinib 10 mg twice daily to 5 mg twice daily: 6-month data from the double-blind, randomised RIVETING study

Ver Presentación

Presentación Oral

Hudesman DP, Torres J, Salese L, Woolcott JC, Mundayat R, Su C, Mosli MH, Allegretti JR Octubre 5, 2021 UEGW 2021 Colitis Ulcerativa

Patient-reported outcome improvement with tofacitinib in the ulcerative colitis OCTAVE clinical programme

Ver Presentación

Materiales de Congresos